有机溶液中的ibuprofen-HPMCAS无形固体分散物的活性片片涂层
Liene Raciborska1, Elżbieta Maria Buczkowska1, Kirils Kukuls1
1Leading Research Group, Faculty of Pharmacy, Riga Stradiņš University, 21 Konsula Street, LV-1007 Riga, Latvia.
Pharmaceutics
|December 31, 2025
概括
使用无形固体分散物的活性片涂层是一种可行的配方策略. 这项研究表明,通过选择适当的有机溶剂和优化涂层参数,可以控制药物剂量的准确性和精度.
科学领域:
- 制药技术 制药技术 制药技术
- 药物输送系统 药物输送系统
- 配方科学科学 配方科学
背景情况:
- 药片的活性涂层是一种研究不足的策略,用于创建固定剂量组合与不溶解药物的无形固体分散.
- 优化溶剂选择对于控制涂层特性和工艺效率至关重要.
研究的目的:
- 为了研究活性药片涂层用于药物加载的可行性,使用布洛芬作为模型药物.
- 评估不同有机溶剂 (乙,乙二,DMSO) 对涂层特性,残留溶剂含量和药物剂量均性 (准确性和精度) 的影响.
主要方法:
- 用两组分喷嘴的实验室面包涂层涂布布洛芬-HPMCAS涂层在安慰剂片上.
- 使用了三种具有不同沸点和蒸发速度的有机溶剂.
- 使用气相色谱量化残留溶剂,用药典评估剂量统一性.
主要成果:
- 其余的乙和乙二低于检测极限 (LOD),而DMSO含量为1.5重量%.
- 药物剂量的准确性随着溶剂沸点的增加而降低 (乙/乙二 > DMSO).
- 用更长的涂层时间和更高的沸点溶剂提高了药物剂量精度,并安装了功率函数 (R2 = 0.9843).
结论:
- 正确的药物剂量,在准确性和精确性方面,可以通过使用研究的设备和方法进行活性药片涂层来实现.
- 涂层过程的持续时间可以调整,以满足所需的剂量精度要求.
相关概念视频
Factors Affecting Dissolution: Polymorphism, Amorphism and Pseudopolymorphism
637
Polymorphism refers to the existence of a drug substance in multiple crystalline forms, known as polymorphs. Recently, this term has been expanded to include solvates (forms containing a solvent), amorphous forms (non-crystalline forms), and desolvated solvates (forms from which the solvent has been removed).
Some polymorphic crystals possess lower aqueous solubility than their amorphous counterparts, leading to incomplete absorption. For instance, the oral suspension of Chloramphenicol, which...
Some polymorphic crystals possess lower aqueous solubility than their amorphous counterparts, leading to incomplete absorption. For instance, the oral suspension of Chloramphenicol, which...
637
Factors Influencing Drug Absorption: Pharmaceutical Parameters
376
Solid dosage forms such as tablets and capsules undergo rigorous manufacturing processes to ensure stability and effectiveness. Their dissolution and absorption properties are influenced significantly by the choice of excipients (inactive ingredients that serve various roles in the formulation), and the methodology applied during production. The manufacturing parameters, such as compression force and granulation techniques, significantly affect dissolution rates. Elevated compression forces...
376
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
131
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
131
Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules
275
Bioequivalence in generic drugs, such as tablets and capsules, refers to their pharmaceutical equivalence to the brand-name counterparts. However, for therapeutic equivalence, manufacturers must also consider physical attributes like size, shape, and weight (FDA Guidance for Industry, December 2003). Discrepancies in these aspects could impact patient compliance and cause medication errors. For instance, swallowing difficulties, often experienced with larger tablets or capsules, can lead to...
275
Factors Affecting Dissolution: Particle Size and Effective Surface Area
1.5K
Dissolution kinetics, an essential aspect of oral drug delivery, is significantly influenced by the drug's particle size. According to the Noyes-Whitney dissolution model, the dissolution rate correlates directly with the drug's surface area. The larger the surface area, the higher the drug's solubility in water, leading to a faster drug dissolution rate. Reducing particle size increases the effective surface area, enhancing the dissolution process. Micronization and nanosizing are...
1.5K
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
180
Body:Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
180


